| Host |
Mouse |
| Klon |
DC10 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Reveal modified Citrate pH 6.0 |
| Positivkontrolle |
Colon, Skin |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasmic |
Cytokeratin 18 (CK18)
|
Biocare Medical |
DC10 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3061A |
-
|
| Host |
Mouse |
| Klon |
DC10 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Reveal modified Citrate pH 6.0 |
| Positivkontrolle |
Colon, Skin |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasmic |
Cytokeratin 18 (CK18)
|
Biocare Medical |
DC10 |
1 ml |
Concentrate |
CE/IVD |
ACI3061C |
-
|
| Host |
Mouse |
| Klon |
DC10 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Reveal modified Citrate pH 6.0 |
| Positivkontrolle |
Colon, Skin |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasmic |
Cytokeratin 18 (CK18)
|
Biocare Medical |
DC10 |
6 ml |
Ready-to-use |
CE/IVD |
API3061AA |
-
|
| Host |
Mouse |
| Klon |
BA17 |
| Format |
Purified |
| Methode |
F, P, WB |
| Vorbehandlung |
Trypsin, Pronase |
| Positivkontrolle |
Normal Breast |
| Verdünnung |
1:50 - 1:100 (P) |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Mammary organoids |
Cytokeratin 19
|
Zytomed Systems GmbH |
BA17 |
200 µg |
Purified |
RUO |
603-2176 |
-
|
| Host |
Mouse |
| Klon |
BA17 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Skin. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Detergent-insoluble extract of human mammary epithelial organoids |
| Lokalisation |
Cytoplasm |
Cytokeratin 19
|
Zeta Corporation |
BA17 |
1.0 ml |
Concentrate |
CE/IVD |
Z2134ML |
-
|
| Host |
Mouse |
| Klon |
BA17 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Skin. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Detergent-insoluble extract of human mammary epithelial organoids |
| Lokalisation |
Cytoplasm |
Cytokeratin 19
|
Zeta Corporation |
BA17 |
7 ml |
Ready-to-use |
CE/IVD |
Z2134MP |
-
|
| Host |
Mouse |
| Klon |
BA17 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Skin. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Detergent-insoluble extract of human mammary epithelial organoids |
| Lokalisation |
Cytoplasm |
Cytokeratin 19
|
Zeta Corporation |
BA17 |
0.5 ml |
Concentrate |
CE/IVD |
Z2134MS |
-
|
| Host |
Mouse |
| Klon |
BA17 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Skin. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Detergent-insoluble extract of human mammary epithelial organoids |
| Lokalisation |
Cytoplasm |
Cytokeratin 19
|
Zeta Corporation |
BA17 |
0.1 ml |
Concentrate |
CE/IVD |
Z2134MT |
-
|
| Host |
Mouse |
| Klon |
Ks20.8 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
proteolytic |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Cytoplasm |
Cytokeratin 20
|
Diagnostic Biosystems |
Ks20.8 |
1 ml |
Concentrate |
CE/IVD |
MOB123 |
-
|
| Host |
Mouse |
| Klon |
Ks20.8 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
proteolytic |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Cytoplasm |
Cytokeratin 20
|
Diagnostic Biosystems |
Ks20.8 |
0.1 ml |
Concentrate |
CE/IVD |
MOB123-01 |
-
|
| Host |
Mouse |
| Klon |
Ks20.8 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
proteolytic |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Cytoplasm |
Cytokeratin 20
|
Diagnostic Biosystems |
Ks20.8 |
0.5 ml |
Concentrate |
CE/IVD |
MOB123-05 |
-
|
| Host |
Mouse |
| Klon |
Ks20.8 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
proteolytic |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2a kappa |
| Lokalisation |
Cytoplasm |
Cytokeratin 20
|
Diagnostic Biosystems |
Ks20.8 |
6 ml |
Ready-to-use |
CE/IVD |
PDM049 |
-
|
| Host |
Mouse |
| Klon |
Ks20.8 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Semi-purified human cytokeratin preparation |
| Lokalisation |
Cytoplasm |
Cytokeratin 20
|
Zeta Corporation |
Ks20.8 |
1ml |
Concentrate |
CE/IVD |
Z2065ML |
-
|
| Host |
Mouse |
| Klon |
Ks20.8 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
- |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Semi-purified human cytokeratin preparation |
| Lokalisation |
Cytoplasm |
Cytokeratin 20
|
Zeta Corporation |
Ks20.8 |
7 ml |
Ready-to-use |
CE/IVD |
Z2065MP |
-
|
| Host |
Mouse |
| Klon |
Ks20.8 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Semi-purified human cytokeratin preparation |
| Lokalisation |
Cytoplasm |
Cytokeratin 20
|
Zeta Corporation |
Ks20.8 |
0.5 ml |
Concentrate |
CE/IVD |
Z2065MS |
-
|
| Host |
Mouse |
| Klon |
Ks20.8 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Semi-purified human cytokeratin preparation |
| Lokalisation |
Cytoplasm |
Cytokeratin 20
|
Zeta Corporation |
Ks20.8 |
0.1 ml |
Concentrate |
CE/IVD |
Z2065MT |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM42 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human KRT20 protein fragment (around aa 196-323) |
| Lokalisation |
Cytoplasm |
Cytokeratin 20
|
Zeta Corporation |
ZM42 |
1 ml |
Concentrate |
CE/IVD |
Z2349ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM42 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
- |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human KRT20 protein fragment (around aa 196-323) |
| Lokalisation |
Cytoplasm |
Cytokeratin 20
|
Zeta Corporation |
ZM42 |
7 ml |
Ready-to-use |
CE/IVD |
Z2349MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM42 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human KRT20 protein fragment (around aa 196-323) |
| Lokalisation |
Cytoplasm |
Cytokeratin 20
|
Zeta Corporation |
ZM42 |
0.5 ml |
Concentrate |
CE/IVD |
Z2349MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM42 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human KRT20 protein fragment (around aa 196-323) |
| Lokalisation |
Cytoplasm |
Cytokeratin 20
|
Zeta Corporation |
ZM42 |
0.1 ml |
Concentrate |
CE/IVD |
Z2349MT |
-
|
| Host |
Mouse |
| Klon |
AE1+AE3+5D3 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Positivkontrolle |
Squamous lung carcinoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasmic |
Cytokeratin AE1+AE3 + CK 5/18
|
Diagnostic Biosystems |
AE1+AE3+5D3 |
6 ml |
Ready-to-use |
CE/IVD |
PDM601 |
-
|
| Host |
Mouse |
| Klon |
34βE12 |
| Format |
ready-to-use |
| Methode |
IHC, FFPE |
| Vorbehandlung |
Citrate o EDTA |
| Verdünnung |
--- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
HMW CK [34βE12] |
| Lokalisation |
Cytoplasmic |
Cytokeratin HMW [34βE12]
|
Biocare Medical |
34βE12 |
6 ml |
ready-to-use |
CE/IVD |
AVI127G |
-
|
| Host |
Mouse |
| Klon |
XM26+LL002+BC4A4 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Reveal modified Citrate pH 6.0 |
| Positivkontrolle |
Prostatic intraepithelial neoplasia PIN |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1+IgG3+IgG2a |
| Lokalisation |
Cytoplasmic and nuclear |
Cytokeratin HMW & p63 Cocktail (Basal Cell Cocktail)
|
Biocare Medical |
XM26+LL002+BC4A4 |
1 ml |
Concentrate |
CE/IVD |
CM210C |
-
|
| Host |
Mouse |
| Klon |
XM26+LL002+BC4A4 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Reveal modified Citrate pH 6.0 |
| Positivkontrolle |
Prostatic intraepithelial neoplasia PIN |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1+IgG3+IgG2a |
| Lokalisation |
Cytoplasmic and nuclear |
Cytokeratin HMW & p63 Cocktail (Basal Cell Cocktail)
|
Biocare Medical |
XM26+LL002+BC4A4 |
6 ml |
Ready-to-use |
CE/IVD |
PM210AA |
-
|
| Host |
Mouse |
| Klon |
34βE12 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Squamous cell carcinoma, prostate. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Solubilized keratin extracted from human stratum corneum |
| Lokalisation |
Membranous and Cytoplasm |
Cytokeratin, HMW
|
Zeta Corporation |
34βE12 |
1.0 ml |
Concentrate |
CE/IVD |
Z2019ML |
-
|
| Host |
Mouse |
| Klon |
34βE12 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Squamous cell carcinoma, prostate. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Solubilized keratin extracted from human stratum corneum |
| Lokalisation |
Membranous and Cytoplasm |
Cytokeratin, HMW
|
Zeta Corporation |
34βE12 |
7 ml |
Ready-to-use |
CE/IVD |
Z2019MP |
-
|
| Host |
Mouse |
| Klon |
34βE12 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Squamous cell carcinoma, prostate. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Solubilized keratin extracted from human stratum corneum |
| Lokalisation |
Membranous and Cytoplasm |
Cytokeratin, HMW
|
Zeta Corporation |
34βE12 |
0.5 ml |
Concentrate |
CE/IVD |
Z2019MS |
-
|
| Host |
Mouse |
| Klon |
34βE12 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Squamous cell carcinoma, prostate. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Solubilized keratin extracted from human stratum corneum |
| Lokalisation |
Membranous and Cytoplasm |
Cytokeratin, HMW
|
Zeta Corporation |
34βE12 |
0.1 ml |
Concentrate |
CE/IVD |
Z2019MT |
-
|
| Host |
Mouse |
| Klon |
AE1/AE3 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Squamous cell carcinoma, prostate. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ + IgG2a /κ |
| Verdünnung |
Human epidermal keratin |
| Lokalisation |
Membranous and Cytoplasm |
Cytokeratin, Pan
|
Zeta Corporation |
AE1/AE3 |
1.0 ml |
Concentrate |
CE/IVD |
Z2061ML |
-
|
| Host |
Mouse |
| Klon |
AE1/AE3 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Squamous cell carcinoma, prostate. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ + IgG2a /κ |
| Verdünnung |
Human epidermal keratin |
| Lokalisation |
Membranous and Cytoplasm |
Cytokeratin, Pan
|
Zeta Corporation |
AE1/AE3 |
7 ml |
Ready-to-use |
CE/IVD |
Z2061MP |
-
|
| Host |
Mouse |
| Klon |
AE1/AE3 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Squamous cell carcinoma, prostate. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ + IgG2a /κ |
| Verdünnung |
Human epidermal keratin |
| Lokalisation |
Membranous and Cytoplasm |
Cytokeratin, Pan
|
Zeta Corporation |
AE1/AE3 |
0.5 ml |
Concentrate |
CE/IVD |
Z2061MS |
-
|
| Host |
Mouse |
| Klon |
AE1/AE3 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Squamous cell carcinoma, prostate. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ + IgG2a /κ |
| Verdünnung |
Human epidermal keratin |
| Lokalisation |
Membranous and Cytoplasm |
Cytokeratin, Pan
|
Zeta Corporation |
AE1/AE3 |
0.1 ml |
Concentrate |
CE/IVD |
Z2061MT |
-
|
| Host |
Mouse |
| Klon |
OSCAR |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Squamous cell carcinoma, prostate. |
| Verdünnung |
1:25-100 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Crude cytokeratin extract prepared from RT-4 and MCF-7 cells |
| Lokalisation |
Membranous and Cytoplasm |
Cytokeratin, Pan
|
Zeta Corporation |
OSCAR |
1.0 ml |
Concentrate |
CE/IVD |
Z2539ML |
-
|
| Host |
Mouse |
| Klon |
OSCAR |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Squamous cell carcinoma, prostate. |
| Verdünnung |
- |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Crude cytokeratin extract prepared from RT-4 and MCF-7 cells |
| Lokalisation |
Membranous and Cytoplasm |
Cytokeratin, Pan
|
Zeta Corporation |
OSCAR |
7 ml |
Ready-to-use |
CE/IVD |
Z2539MP |
-
|
| Host |
Mouse |
| Klon |
OSCAR |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Squamous cell carcinoma, prostate. |
| Verdünnung |
1:25-100 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Crude cytokeratin extract prepared from RT-4 and MCF-7 cells |
| Lokalisation |
Membranous and Cytoplasm |
Cytokeratin, Pan
|
Zeta Corporation |
OSCAR |
0.5 ml |
Concentrate |
CE/IVD |
Z2539MS |
-
|
| Host |
Mouse |
| Klon |
OSCAR |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Squamous cell carcinoma, prostate. |
| Verdünnung |
1:25-100 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Crude cytokeratin extract prepared from RT-4 and MCF-7 cells |
| Lokalisation |
Membranous and Cytoplasm |
Cytokeratin, Pan
|
Zeta Corporation |
OSCAR |
0.1 ml |
Concentrate |
CE/IVD |
Z2539MT |
-
|
| Host |
Mouse |
| Klon |
DDG9+CCH2 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Infected Lung |
| Verdünnung |
1:10 - 1:25 |
| Isotyp |
Mouse IgG2a+IgG1 |
| Verdünnung |
Cytomegalovirus infected cell lysate |
| Lokalisation |
Nucleus |
Cytomegalovirus (CMV Cocktail)
|
Diagnostic Biosystems |
DDG9+CCH2 |
0.5 ml |
Concentrate |
RUO |
MOB049-05R |
-
|
| Host |
Mouse |
| Klon |
DDG9+CCH2 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Infected Lung |
| Verdünnung |
1:10 - 1:25 |
| Isotyp |
Mouse IgG2a+IgG1 |
| Verdünnung |
Cytomegalovirus infected cell lysate |
| Lokalisation |
Nucleus |
Cytomegalovirus (CMV Cocktail)
|
Diagnostic Biosystems |
DDG9+CCH2 |
1 ml |
Concentrate |
RUO |
MOB049R |
-
|
| Host |
Mouse |
| Klon |
DDG9+CCH2 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Infected Lung |
| Verdünnung |
1:10 - 1:25 |
| Isotyp |
Mouse IgG2a+IgG1 |
| Verdünnung |
Cytomegalovirus infected cell lysate |
| Lokalisation |
Nucleus |
Cytomegalovirus (CMV Cocktail)
|
Diagnostic Biosystems |
DDG9+CCH2 |
0.1 ml |
Concentrate |
RUO |
MOB049R-01 |
-
|
| Host |
Mouse |
| Klon |
DDG9+CCH2 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Infected Lung |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2a-kappa/1-kappa |
| Verdünnung |
Cytomegalovirus infected cell lysate |
| Lokalisation |
Nucleus |
Cytomegalovirus (CMV Cocktail)
|
Diagnostic Biosystems |
DDG9+CCH2 |
6 ml |
Ready-to-use |
RUO |
PDM075R |
-
|
| Host |
Mouse |
| Format |
Purified |
| Methode |
P, IF, EL |
| Isotyp |
Mouse IgG1 |
Cytomegalovirus (CMV) (gH)
|
Zytomed Systems GmbH |
- |
100 µg |
Purified |
RUO |
603-2188 |
-
|
| Host |
Mouse |
| Format |
Purified |
| Methode |
IF, EL |
| Isotyp |
Mouse IgG1 |
Cytomegalovirus (CMV) Immediate Early Antigen
|
Zytomed Systems GmbH |
- |
100 µg |
Purified |
RUO |
603-2199 |
-
|
| Host |
Mouse |
| Klon |
DAXX-01 |
| Format |
Purified |
| Methode |
F, WB |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Recombinant C-terminal DAXX protein (aa 558-740) |
Daxx
|
Zytomed Systems GmbH |
DAXX-01 |
100 µg |
Purified |
RUO |
604-0008 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Purified |
| Methode |
P, EL, WB |
| Verdünnung |
2.5 µg/mL |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to human Dax-1, conjugated to kKLH |
Daxx
|
Zytomed Systems GmbH |
polyclonal |
50 µg |
Purified |
RUO |
604-0166 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P, WB, IP |
| Vorbehandlung |
- |
| Positivkontrolle |
Muscle, Sarcoma |
| Verdünnung |
1:200 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide mapping near the C-terminus of human desmin. |
| Lokalisation |
Cytoplasm |
Desmin
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
504-2574 |
-
|
| Host |
Rabbit |
| Klon |
SP138 |
| Format |
Concentrate |
| Methode |
P, WB |
| Vorbehandlung |
- |
| Positivkontrolle |
Skeletal muscle |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide derived from the C-terminus of human desmin protein |
| Lokalisation |
Cytoplasm |
Desmin
|
Zytomed Systems GmbH |
SP138 |
0.5 ml |
Concentrate |
RUO |
504-4382 |
-
|
| Host |
Rabbit |
| Klon |
SP138 |
| Format |
Concentrate |
| Methode |
P, WB |
| Vorbehandlung |
- |
| Positivkontrolle |
Skeletal muscle |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide derived from the C-terminus of human desmin protein |
| Lokalisation |
Cytoplasm |
Desmin
|
Zytomed Systems GmbH |
SP138 |
1 ml |
Concentrate |
RUO |
504-4384 |
-
|
| Host |
Rabbit |
| Klon |
ZR240 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Skeletal muscle or rhabdomyosarcoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human full-length DES protein |
| Lokalisation |
Cytoplasm |
Desmin
|
Zeta Corporation |
ZR240 |
1 ml |
Concentrate |
CE/IVD |
Z2536RL |
-
|
| Host |
Rabbit |
| Klon |
ZR240 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Skeletal muscle or rhabdomyosarcoma |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human full-length DES protein |
| Lokalisation |
Cytoplasm |
Desmin
|
Zeta Corporation |
ZR240 |
7 ml |
Ready-to-use |
CE/IVD |
Z2536RP |
-
|
| Host |
Rabbit |
| Klon |
ZR240 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Skeletal muscle or rhabdomyosarcoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human full-length DES protein |
| Lokalisation |
Cytoplasm |
Desmin
|
Zeta Corporation |
ZR240 |
0.5 ml |
Concentrate |
CE/IVD |
Z2536RS |
-
|